Clinical medicine profile
Nystatin pessaries
HMG-CoA reductase inhibitor (statin)
- Route
- ORAL
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Active liver disease / unexplained persistent LFT elevations.
- Pregnancy and breastfeeding.
- Hypersensitivity.
Precautions
- Myopathy/rhabdomyolysis risk rises with dose and interacting drugs.
- Check baseline LFTs
- investigate muscle symptoms with CK.
- Diabetes incidence slight increase — benefits usually outweigh.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
100,000-200,000 units daily for 14 days as pessaries or vaginal cream.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Some high-intensity agents need dose limits in severe CKD.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Monitor LFTs as labelled; discontinue if persistent significant elevation.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (HMG-CoA reductase inhibitor (statin)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Vaginal candidiasis
Adverse effects
- Myalgia, raised LFTs, GI upset.
- Serious: rhabdomyolysis, severe hepatitis, immune-mediated necrotising myopathy (rare).
Drug interactions
Open multi-drug checker ↗- Dose intensity by CV risk.
- Counsel muscle pain reporting.
- Do not stop after lipids improve — long-term CV prevention.
Mechanism & disposition
Nystatin has both fungicidal and fungistatic properties.
Read complete mechanism
Nystatin has both fungicidal and fungistatic properties. It binds to sterols in the cell membrane of the fungus with a resultant change in membrane permeability, allowing leakage of intracellular components and causing cell death.
Lipid effects weeks
Chronic daily therapy
ORAL
Pregnancy, lactation & diet
Contraindicated — stop if pregnancy planned.
Avoid.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.